ReviewWorld journal of pediatrics : WJP2026
Role of CHD chromatin remodelers in heart development.
Review in World journal of pediatrics : WJP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChromodomain helicase DNA-binding (CHD) proteins are ATP-dependent chromatin remodelers that regulate chromatin accessibility, genome organization, and lineage-specific transcription during embryonic development. There are nine members of this family of proteins. Increasing genetic and functional evidence links mutations in multiple CHD genes to congenital-heart disease, arrhythmias, and cardiomyopathies. However, the stage-specific contributions of individual CHD-family members to cardiac development and functional maturation remain incompletely defined. DATA SOURCES: This narrative review summarizes studies retrieved from the PubMed database that investigate CHD chromatin remodelers in heart development and cardiac disease, with an emphasis on genetic models, developmental analyses, and recent multi-omics approaches.
resultsAvailable evidence indicates that distinct CHD-family members contribute to cardiac development with different levels of support across human genetics, in vivo models, and stem-cell systems. CHD7 has the strongest combined evidence base, including human syndromic genetics and mouse lineage-specific studies, supporting roles in enhancer accessibility, second-heart-field or neural-crest programs, outflow-tract morphogenesis, and later cardiomyocyte maturation. CHD3 and CHD4, as ATPase subunits of the nucleosome remodeling and deacetylase complex, are supported mainly by mouse developmental studies and emerging human genetic data indicating functions in chamber specification, maintenance of lineage boundary, and developmental gene silencing. For CHD8, direct cardiac evidence remains limited. Available data suggest roles in cardiomyocyte survival, ventricular growth, sarcomeric organization, and metabolic homeostasis, but several mechanistic interpretations are inferred from stem-cell or non-cardiac systems. Direct cardiac roles of CHD1, CHD2, CHD5, CHD6, and CHD9 remain poorly defined.
conclusionsCurrent studies support a working model in which CHD remodelers shape enhancer activity, transcription-factor occupancy, and chromatin accessibility during cardiac morphogenesis and maturation. However, coordinated regulation across CHD-family members has not yet been directly established experimentally. Future progress will depend on integrative genetics, time-resolved multi-omics, and cardiac organoid/in vivo validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.